Response to eculizumab in patients with myasthenia gravis recently treated with chronic IVIg: a subgroup analysis of REGAIN and its open-label extension study

BACKGROUND: In the phase III eculizumab for refractory generalized myasthenia gravis REGAIN study [ClinicalTrials.gov identifier: NCT01997229] and its open-label extension (OLE) [ClinicalTrials.gov identifier: NCT02301624], patients with treatment-refractory antiacetylcholine receptor antibody-posit...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacob, Saiju, Murai, Hiroyuki, Utsugisawa, Kimiaki, Nowak, Richard J., Wiendl, Heinz, Fujita, Kenji P., O’Brien, Fanny, Howard, James F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222230/
https://www.ncbi.nlm.nih.gov/pubmed/32426038
http://dx.doi.org/10.1177/1756286420911784

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222230/
https://www.ncbi.nlm.nih.gov/pubmed/32426038
http://dx.doi.org/10.1177/1756286420911784

Ejemplares similares